Monday, March 3, 2008


Enteral Fluconazole Grouping Pharmacokinetics in Patients in the Surgical Intensive Care Unit.
Conclusions: Fluconazole license values in patients in the SICU who had normal renal utility and in those with renal debasement were in provision with previously reported data. Fluconazole measure of human activity was larger and half-life was longer in the SICU colonisation than in healthy subjects.Text edition.

Fluconazole (Diflucan; Pfizer, Inc., New York, NY) is a synthetic triazole antifungal bourgeois with capacity against a wide assortment of pathogenic barm, including Candida albicans and Candida tropicalis. Potentially resistant strains include Candida glabrata, Candida lusitaniae, and Candida krusei. Fluconazole has gained wide clinical assent because of its favorable pharmacokinetics and excellent condom life. In healthy subjects and patients not in an intensive care unit (ICU), fluconazole is almost completely absorbed, with an absolute bioavailability of 90% after oral justice, and exhibits a half-life of approximately 30 work time, which allows for once-daily dosing. Fluconazole is eliminated predominantly by the kidneys; renal permit accounts for 80% of totality permit.

No comments: